In short
Azacitidine, also known as 5-azacytidine or Vidaza, is a drug being studied in various clinical trials for its potential in treating different types of cancer and blood disorders. These trials aim to explore new ways of using azacitidine, either alone or in combination with other drugs, to improve outcomes for patients with conditions such as leukemia, myelodysplastic syndrome (MDS), and certain brain tumors. The research focuses on determining optimal dosing, administration methods, and potential benefits for patients who have not responded well to other treatments.
At a glance
- Drug Name
- Azacitidine (5-azacytidine, Vidaza)
- Primary Conditions Studied
- Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Myelodysplastic Syndrome (MDS), Brain Tumors (Ependymoma)
- Administration Methods
- Subcutaneous injection, Intravenous infusion, Direct infusion into brain ventricle (experimental)
- Combination Therapies
- Sorafenib, PKC412 (Midostaurin), GM-CSF
- Key Objectives
- Determine optimal dosing, Assess safety and efficacy, Explore new administration methods, Evaluate combination therapies
- Notable Findings
- Potential for use in treatment-resistant cancers, Possible benefits in pre-transplant therapy, Experimental use in brain tumor treatment
What is Azacitidine?
Azacitidine is a medication used in the treatment of various blood disorders. It's known by several names, including: 5-Azacytidine 5-AZC Vidaza Ladakamycin Mylosar This drug belongs to a class of medications called hypomethylating agents, which work by affecting how genes are expressed in cells.
What Conditions Does Azacitidine Treat?
Azacitidine is primarily used to treat several blood disorders, including: Myelodysplastic Syndromes (MDS): A group of disorders where the bone marrow doesn't produce enough healthy blood cells. Acute Myeloid Leukemia (AML): A type of blood cancer that starts in the bone marrow. Chronic Myelomonocytic Leukemia (CMML): A rare blood cancer that affects certain white blood cells. These conditions all involve problems with blood cell production or function, which Azacitidine aims to improve.
How Does Azacitidine Work?
Azacitidine works by influencing how genes are expressed in cells. Specifically, it: Blocks certain enzymes that affect DNA, potentially stopping the growth of cancer cells. Helps "turn on" genes that may have been incorrectly turned off in cancer cells. May help restore normal blood cell production in the bone marrow. By affecting gene expression, Azacitidine can potentially slow down or stop the growth of abnormal cells while allowing healthy cells to develop normally.
How is Azacitidine Administered?
Azacitidine can be given in several ways: Subcutaneous (SC) injection: Injected under the skin. Intravenous (IV) infusion: Given directly into a vein. Oral tablets: Taken by mouth (a newer formulation being studied). The most common dosing schedule is 75 mg/m² (based on body surface area) given daily for 7 days, followed by 21 days of rest. This 28-day cycle is typically repeated for several months.
Potential Side Effects
Like all medications, Azacitidine can cause side effects. Common ones may include: Fatigue Nausea and vomiting Diarrhea or constipation Decreased blood cell counts, which can lead to increased risk of infections, bruising, or bleeding Injection site reactions (if given subcutaneously) It's important to discuss potential side effects with your healthcare provider, as they can help manage these issues if they occur.
Current Clinical Trials
Azacitidine is being studied in various clinical trials to: Improve its effectiveness when combined with other drugs. Explore its use in different types of cancer. Develop new formulations, such as oral tablets. Compare it to other treatments or treatment combinations. These trials aim to find better ways to use Azacitidine and potentially expand its use to help more patients.
Combination Therapies
Researchers are exploring how Azacitidine works when combined with other medications. Some combinations being studied include: Azacitidine with Venetoclax for AML. Azacitidine with Lenalidomide for high-risk MDS. Azacitidine with Entinostat for lung cancer. Azacitidine with Glasdegib for AML, MDS, and CMML. These combinations aim to improve treatment outcomes by targeting cancer cells in multiple ways simultaneously.